A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically significant and clinically meaningful improvement in overall survival compared ...

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior im ...